

FLORIDA SOCIETY OF CLINICAL ONCOLOGY THE VOICE OF ONCOLOGY IN FLORIDA

2025



YEAR IN REVIEW



FLORIDA SOCIETY OF CLINICAL ONCOLOGY

THE VOICE OF ONCOLOGY IN FLORIDA



FLASCO MISSION & VISION

The Florida Society of Clinical Oncology (FLASCO) is a statewide non-profit organization committed to facilitating and promoting multidisciplinary efforts to improve patient care in Florida by:

- Championing equitable access to quality cancer care for every citizen of Florida.
- Empowering cancer practitioners with the resources to provide cost-effective, high-quality treatment. Serving as the relentless advocate for Florida cancer patients and their families in legislative arenas.
- Uniting the community by providing a dynamic platform for oncologists, physicians, and healthcare professionals to network, learn, and exchange critical innovations.

FLASCO provides a unified platform to encourage, enhance, and empower collaboration. As tireless advocates, we lead state legislative efforts, fund vital research, and secure the future of oncology by developing tomorrow's leaders. We serve every facet of the care team—from medical oncologists and pharmacists to physician assistants, nurse navigators, social workers, and administrators. We are The Voice of Oncology in Florida.



FLASCO PRESIDENT, DR. MAEN HUSSEIN REFLECTS ON FLASCO'S IMPACT IN 2025

As we close an extraordinary year, I am deeply grateful for our collective achievements. 2025 was defined by explosive growth, strategic evolution, and deepened connection. We didn't just expand our numbers; we expanded our definition of a state society. From securing independence as an education provider to welcoming thousands of new voices, we have proven FLASCO is the essential home for every oncology professional in Florida. These strides were only possible because of your dedication.

- **Historic Membership Growth:** We shattered records by surpassing 8,000 active members—a 48% increase in a single year. A 90% surge in Affiliate Membership united nurses, navigators, and administrators with physicians to form a true multidisciplinary force.
- **CE Provider Status:** In a landmark achievement, FLASCO secured status as an independent CE Provider. This empowers us to accredit programs ensuring our education provides immediate professional value.
- **Record-Breaking Engagement:** Record-Breaking Engagement: We hosted our largest event in history, the Fall Oncology Congress, which drew over 700 attendees. Additionally, the Spring Congress and Business of Oncology Summit welcomed over 450 professionals to discuss AI and practice management to discuss AI and practice management.
- **Innovation in Education:** We continued to grow the Clinical Oncology Series, a nimble roadshow bringing expert updates on GI Cancers, Neuro-Oncology, and ADCs directly to communities across the state.
- **Championing Health Equity:** We inaugurated the Breaking Barriers Summit to close care gaps for underserved populations and supported patients through our Veterans Living With Cancer program.
- **Investing in the Future:** We demonstrated our commitment to the next generation by training 169+ Fellows and Residents through career navigation programs and hosting Rapid Integrations boot camps for APPs.
- **Advancing Research:** We proudly awarded a \$50,000 Young Investigator Award to drive clinical research within Florida, reinforcing our role as a catalyst for scientific discovery.

None of this would be possible without our Board, staff, partners, and you, our members. As we look to 2026, we do so with a stronger foundation than ever. Thank you for your passion, collaboration, and commitment to the patients we serve.



MAEN HUSSEIN, MD

PRESIDENT, FLORIDA SOCIETY OF CLINICAL ONCOLOGY 2024-2025



FLASCO MEMBERSHIPS

A YEAR OF UNPRECEDENTED GROWTH



This flourishing community, united by a shared commitment to advancing cancer care and advocacy, surged to over 8,000 members as more individuals embraced the value of FLASCO's mission. The explosive membership growth—nearly doubling in size since 2023—showcases FLASCO's expanding impact and reinforces its reputation as a trusted leader in advancing cancer-focused initiatives and driving meaningful progress in the field.

	ACTIVE MEMBERS 2022	ACTIVE MEMBERS 2023	ACTIVE MEMBERS 2024	ACTIVE MEMBERS 2025
REGULAR MEMBERS	1921	2021	2343	2,631
ASSOCIATE & STUDENT ASSOCIATE MEMBERS	178	197	222	195
AFFILIATE MEMBERS	1943	1946	2512	4779
COURTESY MEMBERS	294	326	397	422
TOTAL MEMBERS	4336	4490	5474	8,132

ENGAGEMENT & DIGITAL REACH


In 2025, FLASCO's digital footprint expanded beyond the inbox. We launched new multimedia channels to meet our members where they are, whether that's on their commute, in the clinic, or on their phone.

FLASCO FRONTLINE

In 2025, FLASCO solidified its position as the premier source of news for the Florida oncology community. Our digital footprint expanded significantly, with our weekly Frontline newsletter delivering critical clinical updates, legislative alerts, and society news to a rapidly growing audience.

Audience Growth: Readership surged by 47% in 2025, growing from 5,000 to nearly 7,400 oncology professionals weekly.


Total Engagement: Over 300,000 total emails were delivered to the oncology community throughout the year.



THE FLASCO ONCOPOD

Launched this year, The podcast features expert interviews and conversations with oncology "champions and thought leaders," covering topics ranging from groundbreaking clinical advancements to specific FLASCO initiatives.

- 15 Episodes Released
- Over 1,200 Total Downloads




SCAN
TO
LISTEN



PHARMA FOCUS

Our specialized Pharma Focus publications continued to bridge the gap between industry innovation and clinical application, delivering targeted updates on therapeutic breakthroughs directly to our members.

- 32 Editions Published





FLASCO.ORG



**118,925 ACTIVE
USERS**



Instagram

**+100% INCREASE IN
CONTENT
INTERACTIONS**

10,000 TOTAL VIEWS

**459 LIFETIME
FOLLOWERS**

facebook

**24,300 TOTAL
VIEWS**

**5,400 PAGE VISITS
(↑ 108.1% YEAR-
OVER-YEAR)**

**915 LIFETIME
FOLLOWERS**

LinkedIn

**73,057 TOTAL
IMPRESSIONS (100%
ORGANIC REACH)**

**7.64%
ENGAGEMENT RATE
3,996 TOTAL
CLICKS**

**2,334 REACTIONS &
INTERACTIONS**

2025 FLASCO PROFESSIONAL PARTNERSHIP PROGRAMS

STRENGTH THROUGH PARTNERSHIPS AND COLLABORATIONS



As we look back on 2025, we are deeply grateful to the **13 Professional Partnership Program partners** who chose to invest in FLASCO and in the future of oncology in Florida. These partnerships are more than collaborations; they are commitments to progress. Through your engagement and leadership, FLASCO's membership grew to more than 8,000+ oncology professionals, a milestone made possible largely by the strength of our partners. Together, we elevated voices, expanded reach, and strengthened the collective influence of Florida's oncology community while increasing visibility and brand awareness for our partners across the state.

This year, our partnerships helped build a stronger pipeline for the next generation of oncology leaders. Together, we invested in fellows and residents, supported career advancement opportunities for clinicians and allied professionals, and highlighted partner achievements that are making a meaningful difference in local communities. By sharing successes, recognizing growth, and amplifying innovation, we ensured that our partners' work and their impact was seen, celebrated, and elevated across FLASCO's platforms.

Equally important, our collaborations have advanced research, education, and advocacy while addressing real-world challenges faced by oncology practices. Together, we supported research initiatives, fostered collaboration across institutions, and worked to help our partners navigate barriers such as reimbursement complexities, workforce shortages, and evolving oncology healthcare demands. By standing alongside one another, we strengthened not only individual organizations, but the entire oncology ecosystem in Florida, creating lasting progress for professionals today and a stronger foundation for the patients and communities we serve tomorrow.



MOUNT SINAI HEALTH SYSTEM CANCER CENTER "POP-UP" APRIL 2025 | MIAMI BEACH, FL CELEBRATING OUR PARTNERS IN PATIENT CARE



FLASCO had the honor of visiting our esteemed partners at Mount Sinai Health System Cancer Center in Miami Beach, treating their dedicated team to lunch. This visit served as a gesture of sincere appreciation for the outstanding care and unwavering commitment they provide to their patients every day.

LEADERSHIP & COLLABORATION

We extend a special thank you to Dr. Mike Cusnir and Joy Oronos, whose exceptional leadership and steadfast advocacy for FLASCO have been instrumental in fostering collaboration and strengthening our partnership.

The team's warmth and dedication were evident in every aspect of the cancer center. We are incredibly grateful for the inspiring care they deliver and for being such invaluable members of the FLASCO community.





UF HEALTH CANCER INSTITUTE "POP-UP" BUILDING COMMUNITY BEYOND THE CONFERENCE ROOM

JUNE 2025 | GAINESVILLE, FL



In June 2025, the FLASCO team visited the UF Health Cancer Institute in Gainesville, Florida, for a special "Pop-Up" Appreciation Breakfast. This initiative brought FLASCO directly to our professional partners and members, allowing us to personally thank them for their continued membership while strengthening relationships across Florida's oncology community.

The visit increased awareness of FLASCO's mission, membership benefits, and opportunities for engagement, reinforcing the value of a strong, connected state society.

In addition, FLASCO hosted an educational luncheon for Fellows and Residents in collaboration with Johnson & Johnson, featuring a presentation on "Medicare Basics." This educational pop-in bridged the gap between state-level advocacy and the day-to-day clinical realities of early-career oncologists.

Together, these events expanded FLASCO's visibility, deepened member engagement, and strengthened our role as a trusted resource and advocate for oncology professionals across the state.



EDUCATION THAT EMPOWERS

A LEGACY BUILT ON ACCREDITED EXCELLENCE



What We Did

For 15 years, FLASCO has delivered continuing education-accredited programming through partnerships with nationally recognized accreditors. In 2025, this sustained commitment reached a defining milestone when FLASCO achieved independent Continuing Education Provider status. This recognition is the culmination of a comprehensive portfolio that spans large-scale congresses, regional meetings, and virtual education—all designed to be timely, evidence-based, and applicable to clinical practice.

Who It Reached

FLASCO's education engages oncology professionals across the entire state, including physicians, advanced practice providers, pharmacists, nurses, and administrators. By connecting diverse disciplines from community practices, hospital systems, and academic centers, FLASCO has created a shared learning environment that strengthens multidisciplinary collaboration and supports consistency in care delivery.

Why It Matters

Achieving independent CE Provider status secures education as a permanent, member-centered cornerstone of our mission. This accreditation grants FLASCO full stewardship over its educational strategy, allowing for rapid responses to emerging data, new therapeutic approvals, and policy changes. Most importantly, this autonomy ensures that our infrastructure will continue to support Florida's oncology workforce with education that is relevant, responsive, and practice-changing.



EARLY LUNG CANCER SUMMIT

CHALLENGES IN LUNG CANCER & THE NEED FOR ARTIFICIAL INTELLIGENCE & BLOOD BIOMARKERS

JANUARY 24-25, 2025

DIPLOMAT BEACH RESORT, HOLLYWOOD, FL

128

ATTENDEES



PROGRAM CHAIR



LUIS E. RAEZ
MD, FASCO, FACP
MEMORIAL CANCER INSTITUTE

The 2025 Early Lung Cancer Summit gathered multidisciplinary experts to address the most pressing challenges in early-stage lung cancer detection and management.

ARTIFICIAL INTELLIGENCE IN DETECTION

Sessions explored the integration of AI models to identifying incidental nodules and streamline lung cancer screening workflows.

BIOMARKER TESTING


In-depth discussions on the necessity of blood-based biomarkers and next-generation sequencing (NGS) for early-stage patients to guide adjuvant and neoadjuvant therapies.

SURGICAL ADVANCES

Updates on robotic-assisted surgeries and lung-sparing techniques for early-stage disease.

SCREENING BARRIERS

A dedicated working group addressed disparities in lung cancer screening, focusing on rural access and overcoming stigma.



PROGRAM SPONSOR





AHOMPR

14th Annual Puerto Rico Oncology Symposium

FEBRUARY 7-8, 2025

San Juan Marriott Resort
& Stellaris Casino

154 ATTENDEES



PROGRAM CHAIR



GERARDO COLON-OTERO, MD
MAYO CLINIC FLORIDA

Connecting Puerto Rican and mainland US oncology professionals, this event fostered clinical exchange, research collaboration, and solutions for Hispanic health disparities.

RESEARCH SHOWCASE

A robust poster session featuring research from fellows and residents on cancer disparities and clinical outcomes in Puerto Rico.

CLINICAL UPDATES

Expert-led sessions covering the latest standard-of-care updates in breast, lung, and gastrointestinal cancers tailored to regional patient needs.

NETWORKING

The event successfully connected academic researchers with community oncologists to foster future clinical trial collaborations.


FLASCO INITIATIVES ARE SUPPORTED BY
OUR 2025 CORPORATE PARTNERSHIPS





FLASCO 2025
CLINICAL
ONCOLOGY SERIES
GI CANCER UPDATES
FEBRUARY 8, 2025
WESTIN TAMPA WATERSIDE

74
ATTENDEES



This one-day event provided a deep dive into systemic and surgical management strategies for upper GI, pancreatic, colon, and hepatocellular cancers.

UPPER GI

Advances in systemic therapy for gastroesophageal cancers and contemporary surgical management of esophageal cancer.

PANCREATIC CANCER

Perioperative approaches in early-stage disease and insights into systemic/personalized therapies for 2024.

COLON CANCER

Targeted therapies focusing on HER2 and KRAS in colorectal cancer (CRC).

HEPATOCELLULAR CARCINOMA (HCC)

Practical approaches to locoregional versus systemic therapies.

CHOLANGIOCARCINOMA

The role of immunotherapy, combination approaches, and biomarker-driven treatments.

NEUROENDOCRINE TUMORS (NETS)

New directions in PRRT and the current landscape for high-grade NEC.



PROGRAM SPONSORS





Great Strides Together Rapid Integrations

MARCH 8-9, 2025

MOFFITT CANCER CENTER, TAMPA, FL

122 ATTENDEES



A dual-program weekend designed to support the "Team Approach" to oncology care.

GREAT STRIDES TOGETHER

Building the physician-APP relationship and multidisciplinary care models.

HIGHLIGHTS

Sessions on "The Art of the Difficult Conversation," managing survivorship, and navigating the complexities of oral oncolytics.

Interactive "Exhibit Hall Bingo" and networking mixers to foster peer connections.

RAPID INTEGRATIONS

An "Introduction to Oncology" boot camp for APPs new to the specialty.

CURRICULUM

Covered the basics of chemotherapy safety, oncologic emergencies, billing/coding 101, and introduction to clinical trials.



PROGRAM SPONSORS





FELLOWS & RESIDENTS

TRAINING PROGRAM

MARCH 22, 2025

JW MARRIOTT ORLANDO BONNET CREEK,
ORLANDO, FL

120

ATTENDEES



PROGRAM CHAIR



RICK MCDONOUGH, MD
FLORIDA CANCER SPECIALISTS
& RESEARCH INSTITUTE

This exclusive event was designed to prepare the next generation of oncologists for the transition from training to practice.

THE BUSINESS OF ONCOLOGY

Understanding contract negotiations, billing, coding, and practice management.

CAREER NAVIGATION

Panels on choosing between academic, community, and industry career paths.

RESEARCH TO REALITY

How to conduct and interpret clinical trials in a community setting.

FINANCIAL WELLNESS

Strategies for managing student loans and personal finance for early-career physicians.



PROGRAM SPONSORS





2025 SPRING CONGRESS & BUSINESS OF ONCOLOGY SUMMIT

APRIL 4-5, 2025

JW MARRIOTT ORLANDO BONNET CREEK, ORLANDO, FL

450

ATTENDEES



The 2025 Spring Congress & Business of Oncology Summit united 506 attendees to navigate the future of cancer care, shining a spotlight on innovations like AI in practice, value-based care strategies, and legislative reform.

AI IN PRACTICE

Practical applications of AI for cancer detection and administrative efficiency.

VALUE-BASED CARE

Navigating new reimbursement models and practice sustainability.

THE EVOLVING LANDSCAPE

Updates on PBM reform and legislative changes affecting Florida practices.

CLINICAL HIGHLIGHTS

"Emerging Therapeutics and Managing the Long-Term Impact of Immunotherapy"

RESEARCH

Featured 12 poster presentations from fellows and residents and an additional 16 from our industry partners

RECOGNITION

Celebration of FLASCO Travel Award winners and introduction of new Professional Partners.

FLASCO INITIATIVES ARE SUPPORTED BY OUR 2025 CORPORATE PARTNERSHIPS





2025 SPRING CONGRESS & BUSINESS OF ONCOLOGY SUMMIT

APRIL 4-5, 2025

JW MARRIOTT ORLANDO BONNET CREEK, ORLANDO, FL

450

ATTENDEES





LEADERSHIP STRATEGY SUMMIT

FLASCO BOARD RETREAT JUNE 2025 | ST. PETERSBURG, FL



The FLASCO Board of Directors, Committee Chairs, and Liaisons gathered for the annual Leadership Strategy Summit. This retreat focused on reviewing the society's strategic plan, identifying future growth areas, and fostering team cohesion.

KEY OUTCOMES

The retreat produced clear alignment around FLASCO's core strengths and future priorities, reinforcing its role as a unifying, multidisciplinary oncology society while identifying specific gaps in awareness, engagement, and geographic reach that must be addressed.

LEADERSHIP OLYMPICS

A highlight of the retreat was the "Leadership Olympics" team-building activity. Board members were divided into teams to complete creative challenges, fostering camaraderie and communication in a fun, relaxed setting.

FUTURE VISION

There was strong agreement on the importance of leaders modeling engagement and intentionally identifying and developing the next generation of FLASCO champions to sustain long-term impact across Florida.






FLASCO 2025 CLINICAL ONCOLOGY SERIES NEURO-ONCOLOGY

AUGUST 9, 2025

JW MARRIOT ORLANDO GRAND LAKES,
ORLANDO, FL

38

ATTENDEES



PROGRAM CHAIRS



MANMEET AHLUWALIA
MD, MBA, FASCO
BAPTIST HEALTH SOUTH
FLORIDA



ASHLEY GHIASEDDIN
MD, FAAN
UF COLLEGE OF MEDICINE
FLORIDA

This session bridged the gap between novel technologies and practical management of neurologic complications in cancer care.

GLIOMAS

Molecular classification, precision oncology in low-grade gliomas, and glioblastoma management.

NOVEL TECHNOLOGIES

Surgical strategies to conquer the blood-brain barrier and Tumor Treating Fields.

BRAIN METASTASES


Advances in targeted therapies and the role of SRS/WBRT.

NEUROLOGIC COMPLICATIONS

Managing toxicities from ICIs and CAR-T, with specific consideration to ICANS.

COMMUNITY FOCUS

A panel on bringing clinical trials to the community setting.



PROGRAM SPONSORS






FLASCO 2025 CLINICAL ONCOLOGY SERIES CLASSICAL HEMATOLOGY

AUGUST 23, 2025

JW MARRIOT ORLANDO GRAND LAKES,
ORLANDO, FL

61

ATTENDEES



PROGRAM CHAIRS



MICHAEL JAGLAL, MD
MOFFITT CANCER CENTER



EWA WYSOKINSKA, MD
MAYO CLINIC FLORIDA

This event focused on non-malignant hematology updates: thrombosis, bleeding disorders, and blood cell pathologies.

THROMBOSIS

ASH Guideline updates on thrombophilia testing and anticoagulation management in cancer patients.

BLEEDING DISORDERS

Workup of inherited and acquired bleeding disorders and updates in hemophilia management.

RED BLOOD CELL TOPICS

Autoimmune Hemolytic Anemia and Sickle Cell Disease.

WHITE BLOOD CELL TOPICS

Clonal Hematopoiesis (CHIP/CCUS) and Isolated Neutropenia.

PLATELET TOPICS

Updates on ITP management, TMA Syndromes, TTP, and aHUS.

RARE DISEASES

New medications in classical hematology and approaches to iron overload.



PROGRAM SPONSORS





FLASCO 2025 CLINICAL ONCOLOGY SERIES


ANTIBODY-DRUG CONJUGATES

SEPTEMBER 13, 2025

HOTEL COLONNADE, CORAL GABLES, FL

45

ATTENDEES



PROGRAM CHAIR



EDGARDO SANTOS

MD, FACP, FCCP, FASCO

THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION

2026 FLASCO PRESIDENT

This specialized series explored how ADCs are revolutionizing the treatment landscape across multiple tumor types, with a strong focus on toxicity management and efficacy.

TOXICITY PROFILES

Deep dives into toxicities associated with specific payloads including SN-38, Deruxtecan, Calicheamicin, and MMAE.

BIOMARKERS & DEFINITIONS

The pathologist's perspective on HER2 overexpression, amplification, and "low/ultra-low" definitions.

DISEASE-SPECIFIC EFFICACY

ADCs in NSCLC, SCLC, Genitourinary malignancies, Breast Cancer, Acute Leukemias, and Lymphomas.

COST & AGNOSTIC INDICATIONS

Cost-effectiveness of ADCs and HER2 as an agnostic biomarker.



PROGRAM SPONSORS





FLASCO 2025 FALL ONCOLOGY

Congress

726 ATTENDEES



JW MARRIOTT ORLANDO BONNET CREEK,
ORLANDO, FL

APRIL 4-5, 2025

The largest FLASCO event of the year, achieving record-breaking attendance. The Fall Congress featured five specialized tracks to cater to the diverse needs of the oncology workforce.



MULTIDISCIPLINARY TRACK

Clinical updates for physicians.

PHARMACY TRACK

Updates for pharmacists on new drug approvals and stewardship.

APP TRACK

Advanced clinical management for NPs and PAs.

NURSE/NAVIGATOR TRACK

Patient navigation strategies and nursing best practices.

ADMINISTRATOR TRACK

Practice management, coding, and policy updates.

NIGHT OF PHILANTHROPY & EXHIBIT EXPERIENCE

In support of the FLASCO Foundation.

FLASCO INITIATIVES ARE SUPPORTED BY
OUR 2025 CORPORATE PARTNERSHIPS






FLASCO 2025
FALL
ONCOLOGY
Congress



726

ATTENDEES



APRIL 4-5, 2025

JW MARRIOTT ORLANDO BONNET CREEK,
ORLANDO, FL





FLASCO BREAKING BARRIERS SUMMIT

NOVEMBER 7-8, 2025

HILTON MIAMI AVENTURA, AVENTURA, FL

128 ATTENDEES



PROGRAM CHAIR



LUIS E. RAEZ

MD, FASCO, FACP
MEMORIAL CANCER INSTITUTE

A summit dedicated to health equity, focusing on improving cancer care access for rural, veteran, and underserved populations in Florida.

KEY HIGHLIGHTS

BREAKING DOWN THE BARRIERS

Strategies to identify and mitigate patient barriers to cancer care.

CLINICAL TRIAL DIVERSITY



Actionable steps to increase diversity of representation in cancer research.

COMMUNITY ENGAGEMENT

Panels featuring community leaders and patient advocates discussing trust-building in underserved areas.

LEGISLATIVE ACTION

Developing a policy roadmap to support equitable care delivery at the state level.



PROGRAM SPONSORS



abbvie



AMGEN

Bristol Myers Squibb





OCN TEST PREP COURSE


SPRING: MAY 17-18, 2025 | MIAMI, FL
FALL: NOVEMBER 15-16, 2025 | TAMPA, FL

67

ATTENDEES
(MAY)

49

ATTENDEES
(NOVEMBER)



PROGRAM FACULTY



MARY MACKRELL
RN, MSN, MED, OCN,
BMTCN



MARY LEBAN
MED, MSN, APN, FNP-BC,
OCN, PMGT-BC, CNE

FLASCO recognizes the unique challenges and complexities nurses face when preparing for the Oncology Certified Nurse (OCN®) examination. Balancing demanding clinical responsibilities with the rigorous preparation required for certification can be overwhelming. In response to these challenges, FLASCO proudly developed and offered two OCN® preparation courses in 2025, specifically designed to support our members and strengthen their readiness for success.

The level of difficulty of the OCN® exam varies depending on an individual's experience, foundational knowledge, and comfort with standardized testing. The exam is widely recognized for its comprehensive scope, covering a broad range of oncology nursing topics and integrating both inpatient and outpatient clinical scenarios.

FLASCO is proud to support the professional and academic growth of our members by providing educational opportunities that build confidence, promote certification success, and advance excellence in oncology nursing.

FLASCO INITIATIVES ARE SUPPORTED BY OUR 2025 CORPORATE PARTNERSHIPS



PO is experiencing severe pain and nausea that cannot be controlled adequately. The palliative care physician has ordered terminal sedation. Which of the following agents will the nurse anticipate administering?

- A. Morphine
- B. Fentanyl
- C. Benzodiazepine
- D. Antidepressant




FINANCIAL TOXICITY WEBINAR SERIES

AUGUST 19 - SEPTEMBER 25, 2025

189

ATTENDEES



Kickstarting the conversations of the Fall Congress Administrator Track, this four-part series gathered cross-sector experts to discuss strategies for reducing the financial burden for cancer patients.

PHARMACEUTICAL INDUSTRY PERSPECTIVE

AUGUST 19, 2025



RICHARD FAHRER
PFIZER



NIKOLE JEFFREY
GENENTECH

PATIENT ADVOCACY PERSPECTIVE

AUGUST 26, 2025



SETH BERKOWITZ
LCSW, CCLS
BLOOD CANCER UNITED



JOANA FAWZY DORAN
ESQ.
TRIAGE CANCER

COMMUNITY PRACTICE PERSPECTIVE

SEPTEMBER 4, 2025



GAIL ERENTREICH
CANCER CARE CENTERS OF BREVARD



SHELLI JOHNSON
CANCER CARE CENTERS OF BREVARD

ACADEMIC-BASED PERSPECTIVE

SEPTEMBER 25, 2025



EDDA SANZ
MSW
SYLVESTER COMPREHENSIVE CANCER CENTER



UPDATES IN IDHM GLIOMAS

WEBINAR

JANUARY 28, 2025

This high-impact session was established through the initiative of FLASCO's Neuro Oncology Captain, Dr. Ashley Ghiaseddin. Following his attendance at a national conference supported by FLASCO, Dr. Ghiaseddin developed this webinar to share critical best practices and emerging knowledge with society members.

The presentation provided a comprehensive overview of the evolving therapeutic landscape for IDH-mutant gliomas, specifically highlighting the paradigm shift brought about by the FDA approval of Vorasidenib in August 2024.

UPDATES IN IDHM GLIOMAS

WATCH ON



PROGRAM SPEAKER



**ASHLEY GHIASEDDIN
MD, FAAN**

UF COLLEGE OF MEDICINE

INDIGO STUDY ANALYSIS

A deep dive into the Phase 3 study results, showing significant improvements in progression-free survival and time to next intervention with Vorasidenib.

MOLECULAR PROFILING

The critical role of Next-Generation Sequencing (NGS) in diagnosing and identifying targetable mutations in gliomas. Treatment Paradigms:

Discussing the shift from "watch and wait" to active management for low-grade, IDH-mutant gliomas to delay the need for toxic chemo-radiation.

Multidisciplinary Strategies: The importance of collaboration between neuro-oncologists, surgeons, and radiation oncologists in managing complex brain tumor cases.



ADVANCES IN TREATMENT OPTIONS FOR TENOSYNOVIAL GIANT CELL TUMOR (TGCT)

VIRTUAL WEBINAR VIA ZOOM

JULY 31, 2025

Presented by the FLASCO Rare Disease Committee, this webinar reviewed the latest targeted therapies for TGCT. Topics included clinical indications for newly approved agents, mechanisms of action, and safety considerations for patient management.

PROGRAM SPEAKER

TREATMENT OPTIONS FOR TENOSYNOVIAL GIANT CELL TUMOR

VIRTUAL WEBINAR VIA ZOOM



LEIGHTON ELLIOTT, MD
UF COLLEGE OF MEDICINE

RARE DISEASE COMMITTEE

Established in 2025, the Rare Disease Ad Hoc Committee created a dedicated forum to address education, awareness, and collaboration around rare oncologic and hematologic diseases. The committee began integrating rare disease content into FLASCO's broader educational ecosystem.

- First educational webinar delivered
- Rare disease topics incorporated into FLASCO programming



ADVOCACY IN ACTION

ADVANCING ACCESS TO CARE: FLASCO'S DIALOGUE WITH SENATE HEALTH CHAIR COLLEEN BURTON



On October 24th FLASCO had the honor of meeting with the Chair of the Florida Senate Health Committee, Senator Colleen Burton, and her team to discuss strategies for expanding access to cancer research, clinical trials, and comprehensive, high-quality care throughout our state. We appreciate the open dialogue and the shared dedication to ensuring every Floridian has access to innovative cancer treatment and support, regardless of where they live.

FLASCO VIRTUAL ADVOCACY ROUNDTABLE

In December 2025, FLASCO convened a Virtual Advocacy Roundtable to bring together oncology clinicians, health system leaders, professional societies, and corporate partners to align on legislative and policy issues affecting cancer care in Florida ahead of the 2026 legislative session. The roundtable served as a forum for information sharing, coalition building, and strategic discussion, reinforcing FLASCO's role as a convener at the intersection of clinical care, policy, and patient access.

By convening diverse stakeholders and translating discussion into actionable follow-up, the 2025 FLASCO Advocacy Roundtable strengthened the foundation for proactive, clinician-informed advocacy. This work ensures that FLASCO remains well positioned to educate policymakers, respond to emerging legislative threats, and advocate effectively for policies that protect patient access and support high-quality cancer care across Florida.



VETERANS

g With Cancer



83

ATTENDEES

AUGUST 16, 2025

HILTON UF CONFERENCE CENTER,
GAINESVILLE, FL



The 3rd Annual Veterans g With Cancer was an advocacy-focused educational program featuring leading oncology physicians and subject matter experts who provided veterans and their caregivers with critical education about cancer diagnoses and treatment pathways. The program delivered comprehensive information and practical resources designed to help participants navigate the complex physical, psychosocial, and economic challenges associated with cancer. For veterans, the impact of cancer often extends well beyond physical health, affecting mental well-being, family relationships, and financial stability. This program addressed these multifaceted challenges by equipping veterans and caregivers with the support, tools, and skills needed to improve overall quality of life. In addition to educational sessions, the program included exhibitor engagement, resource sharing, networking opportunities, and provided breakfast and lunch, fostering a supportive environment for connection, learning, and empowerment.

PROGRAM SPONSORS





LIVING WITH ROS-1 POSITIVE LUNG CANCER

WEBINAR

NOVEMBER 17, 2025 | 5 PM EST

82

ATTENDEES

The next webinar in flasco's "Living With" series provided patients and caregivers with critical updates on ROS1-positive non-small cell lung cancer (NSCLC). The session bridged the gap between complex genetic science and daily survivorship, highlighting the rapid evolution of targeted therapies in 2025.



TOPICS COVERED

- Understanding ROS1-positive lung cancer and its genetic drivers
- The importance of comprehensive biomarker testing (DNA & RNA)
- Advances in targeted therapies and treatment resistance
- Managing brain metastases and crossing the blood-brain barrier
- Patient empowerment, advocacy, and Q&A with experts

PROGRAM SPEAKERS



ANDREW CIUPEK
PHD
GO2 FOR LUNG
CANCER



MARTIN DIETRICH
MD, PHD
CANCER CARE
CENTERS OF
BREVARD



LUIS E. RAEZ
MD, FASCO, FACP
MEMORIAL
CANCER INSTITUTE



JULIA ROTOW
MD
DANA FARBER
CANCER INSTITUTE

PROGRAM SPONSORS



WATCH ON





LIVING WITH GIST (GASTROINTESTINAL STROMAL TUMOR)

WEBINAR

MAY 20, 2025 | 5:00 PM – 6:30 PM EST

61

ATTENDEES

The latest installment of FLASCO's "Living With" series brought together patients, caregivers, and leading experts for a comprehensive overview of Gastrointestinal Stromal Tumors (GIST). Hosted in partnership with Deciphera, this session focused on bridging the gap between clinical expertise and patient experience, empowering attendees with the knowledge and resources needed to become their own best advocates.



PROGRAM SPEAKERS



ANDREW BROHL, MD
MOFFITT CANCER CENTER



SARA ROTHSCHILD
THE LIFE RAFT GROUP



**JONATHAN TRENT
MD, PHD**
UNIVERSITY OF MIAMI
HEALTH SYSTEM

EXPERT PERSPECTIVES

Hearing directly from leading GIST specialists on the latest in care and disease management.

INTERACTIVE SUPPORT

A dedicated live Q&A session addressing specific patient and caregiver concerns.

ADVOCACY & RESOURCES

Gaining critical tools and knowledge to navigate the GIST journey with confidence.

WATCH ON





LIVING WITH NPC (NASOPHARYNGEAL CARCINOMA)

WEBINAR

APRIL 2, 2025 | 5:00 PM – 6:30 PM EST

43

ATTENDEES

This edition of the FLASCO "Living With" series provided a comprehensive educational forum for those affected by Nasopharyngeal Carcinoma (NPC). Hosted in partnership with Coherus, the webinar brought together renowned experts to discuss the unique biology of NPC, the latest advancements in treatment, and practical strategies for survivorship. The session aimed to empower patients with the knowledge needed to navigate their diagnosis and become effective self-advocates.



PROGRAM SPEAKERS



WATCH ON
 YouTube



MARSHALL POSNER, MD
TGH/CANCER CENTER OF
SOUTH FLORIDA

SHRAVAN KANDULA, MD
RADIATION ONCOLOGIST
ADVENT HEALTH

LESLIE WORONA
ADVANCED PRACTICE
PROVIDER MOUNT SINAI
HOSPITAL

UNDERSTANDING NPC

An overview of the disease's epidemiology, risk factors (including Epstein-Barr Virus), and clinical presentation.

TREATMENT LANDSCAPE

In-depth discussions on the roles of radiation, chemotherapy, and emerging immunotherapy options for various stages of the disease.

SYMPTOM MANAGEMENT

Practical advice from advanced practice providers on managing side effects such as mucositis, nutrition/hydration challenges, and neuropathy.

SURVEILLANCE & FOLLOW-UP

The importance of monitoring EBV DNA titers and imaging for long-term care.

LIVE Q&A

A dedicated session addressing specific patient concerns regarding survivorship and quality of life.



FLASCO WHITE PAPER

OPERATIONALIZING BISPECIFICS

WHAT WE DID

Developed by multidisciplinary oncology experts from across Florida, the paper provides practical, clinician-driven guidance to support the safe and effective delivery of bispecific antibodies in community oncology settings. This white paper represents the evolution of a corporate partnership initiative launched in 2024, which expanded in scope and impact throughout 2025 through continued collaboration, refinement, and dissemination.

The white paper was released in March 2025 and structured to address the full spectrum of challenges associated with bispecific implementation, including clinical management, operational readiness, and multidisciplinary coordination. To broaden accessibility and accelerate adoption, FLASCO published a concise summary guide in October 2025 and followed with a dedicated podcast episode in November 2025 featuring two of the paper's coauthors. Together, these formats ensured the guidance was not only available, but actionable.

WHO IT REACHED

This work was designed for oncology teams practicing across Florida, with particular relevance for community-based physicians, advanced practice providers, pharmacists, nurses, and administrators navigating the integration of novel immunotherapies. By addressing both clinical and operational considerations, the guidance speaks to the full care team responsible for delivering bispecific therapy safely outside of academic centers.

Through publication, summary dissemination, and audio-based discussion, FLASCO extended the reach of this work to multidisciplinary stakeholders involved in patient selection, toxicity management, emergency preparedness, pharmacy operations, and care coordination. The project also reinforced collaboration between academic and community practices by offering a shared framework for delivering advanced lymphoma care closer to home.

WHY IT MATTERS

Bispecific antibodies represent a transformative advance in lymphoma treatment, but their real-world adoption has been limited by concerns around safety, infrastructure, and readiness. FLASCO's consensus paper directly addresses these barriers by translating emerging evidence and frontline experience into practical guidance tailored to community oncology practice.

As FLASCO's first consensus white paper, this initiative establishes a new model for clinician-led thought leadership within the organization. It demonstrates FLASCO's ability to move innovation from concept to implementation, ensuring that advances in cancer therapy are matched by the systems, knowledge, and collaboration needed to deliver them safely and equitably. Most importantly, this work supports expanded patient access to life-changing therapies across Florida, reinforcing FLASCO's mission to advance high-quality cancer care statewide.

FLASCO
OncoPod 



From Paper to Practice:
FLASCO's Consensus Paper
on Bispecifics Released

READ
WHITEPAPER



2025 FLASCO AWARD RECIPIENTS

Progress in our field is never a solo journey; it is powered by a community where your voice matters and your impact is deeply felt. These awards celebrate the extraordinary members who embody the power of belonging and drive the movement to shape the next chapter of oncology together.

FLASCO DISTINGUISHED SERVICE AWARD



The FLASCO Distinguished Service Award is reserved for individuals whose dedication, leadership, and sustained contributions have left a lasting mark on both our organization and the broader oncology community.

NOMAN ASHRAF, MD
TGH CANCER INSTITUTE

FLASCO ABOVE & BEYOND AWARD



The FLASCO Above & Beyond Award honors a FLASCO member who exemplifies unwavering dedication, exceptional leadership, and a true spirit of service.

ASHLEY GHIASEDDIN MD, FAAN
UF COLLEGE OF MEDICINE

FLASCO ADVOCATE OF THE YEAR AWARD



The FLASCO Advocate of the Year Award honors a healthcare professional who uses their voice and influence to advance cancer care policy, expand access to treatment, and drive meaningful change for patients and providers alike.

HEATHER AUGUSTYNIK
DNP, APRN, FNP-C
BAPTIST MD ANDERSON CANCER CENTER

FLASCO BEACON AWARD



The FLASCO Beacon Award is presented to a member who serves as a steady and inspiring light in the oncology community, guiding others through mentorship, leadership, and innovation.

DINA DUMERCY-MCHENRY
PHARMD, MBA, BCOP, CSSGB
MIAMI CANCER INSTITUTE | BAPTIST HEALTH SOUTH FLORIDA

2025 FLASCO AWARD RECIPIENTS

FLASCO TRAILBLAZER AWARD



The FLASCO Trailblazer Award honors a visionary leader who pushes boundaries, sparks progress, and paves new paths in oncology through research, education, and clinical innovation.

**EDGARDO SANTOS
MD, FACP, FASCO**

*THE ONCOLOGY INSTITUTE OF HOPE
AND INNOVATION*

2025 DOROTHY GREEN PHILLIPS LEGACY AWARD



When Dorothy Green Phillips retired as Executive Director in 2019, FLASCO established a special award to honor her enduring legacy and to recognize the pioneers who continue to lead and shape the future of oncology in our community.

THOMAS MARSLAND, MD
UNIVERSITY OF FLORIDA

Congratulations!





2025 Travel Award Recipients



Each year, FLASCO provides members with opportunities to apply for educational travel awards that support attendance at FLASCO and National Oncology Meetings such as ASCO, HOPA, and ASTRO. Congratulations to the recipients recognized below!



SUSET ALUMINAS DE ARMAS, MD



STEPHANIE ATALLAH, PHARM D



ARLET BACALLAO, PHARM D



FIRAS BAIDOUN, MD, FACP



ANDREW BARNHART, PHARM D



VERA BULAKHOVA, PHARM D



ETHAN EILO, PHARM D



RYAN FALCON, PHARM D



SARA GHADERI, PHARM D



CHINMAY JANI, MD



SOOHYUN KIM, PHARM D



JESSICA MCMILLAN, DNP, APRN, FNP-BC



BRIANNE MILLER, PHARM D



ROBIN PARK, MD



JUDE PIERRE PHARM D



NANCY PITRUZZELLO, DNP, APRN, FNP-BC, CPAN



AARON RITTER, PHARM D



DAYANSHLY RIVERA RIVERO, PHARM D



MOAZZAM SHAZAD, MD



JOSE VALDES LEDESMA, PHARM D



JAMES YU, MD

Congratulations!

RESEARCH WORKING GROUP

A MILESTONE YEAR: LAUNCHING THE FUTURE OF FLORIDA CANCER RESEARCH



RESEARCH WORKING GROUP

In 2025, the Research Working Group achieved a major milestone with the official launch of the FLASCO Emerging Oncology Leaders Research Grant. This strategic initiative was developed to address a critical need within the state's oncology ecosystem: retaining top medical talent and providing essential funding for early-career investigators pursuing high-impact clinical and translational research.

To ensure excellence, the Working Group spearheaded a rigorous peer-review process to evaluate proposals from across the state. The high quality of submissions underscored the depth of research talent currently residing in Florida and established a solid foundation for the program's future expansion.

INAUGURAL GRANT RECIPIENT

FLASCO is proud to award the inaugural **\$50,000** grant to **Juan B. Blaquier, MD**, of the **University of Miami Sylvester Comprehensive Cancer Center**. This funding supports his pivotal research titled "**Mechanisms of Acquired Resistance to IDH Inhibitors in Gliomas**," which aims to uncover new therapeutic targets to improve survival rates for patients facing this diagnosis.

MEMBERS OF THE MONTH

January



SIKANDER AILAWADHI, MD

February



AHMED ZAKARI, MD

March



ALYSSIA CREWS, MBA

April



RICK MCDONOUGH, MD

May



**CINDY BOWMAN
MSN, RN, OCN**

June



MICHAEL JAGLAL, MD

July



LUCIO GORDAN, MD

August



**MANMEET AHLUWALIA
MD, MBA**

September



**EDGARDO SANTOS
MD, FACP, FASCO**

October



LUIS E. RAEZ, MD

Congratulations!



FLASCO NURSES MIXER

CELEBRATING CONNECTION, CAMARADERIE, AND DEDICATION TO SERVICE

JUNE 2025 | FORT LAUDERDALE, FL



FLASCO hosted an unforgettable evening celebrating our oncology nursing community.

The FLASCO Mixer began with a scenic sunset cruise, where members relaxed along the waterways while enjoying music, dancing, and meaningful conversation. The evening continued with an exclusive red-carpet dining experience at Tamarindo Harbor Italian Restaurant, creating a memorable atmosphere of recognition and celebration. More than a social event, the mixer exemplified FLASCO's mission to support the hard work of our members by fostering connection, wellness, and professional camaraderie. We understand that the intensity of oncology nursing can lead to burnout, and intentional gatherings like this provide essential opportunities for rest, reflection, and peer support. By investing in these experiences, FLASCO strengthens professional bonds, reinforces a sense of belonging, and enhances the overall well-being of our members.






2025 FLASCO ONCOLOGY CAPTAINS

SUPPORT, COUNSEL, LEADERSHIP

As Oncology Captains, these FLASCO Members served as **FLASCO's thought leaders** for disease-specific initiatives and special projects. These members provided support, counsel, and leadership regarding their specialty disease states. These initiatives encompassed support on Corporate Partnership projects, serving as faculty members or references, advocacy support, program planning, and other specialty-focused initiatives throughout the year. Thank you to our 2025 FLASCO Oncology Captains for all your support!



TIAGO BIACHI
MD, PHD
COLON



ANDREW BROHL, MD
SARCOMA



ROHAN GARHE, MD
PROSTATE



COLLEEN GAUGHAN, MD
ESOPHOGEAL



ASHLEY GHIASEDDIN
MD, FAAN
NEURO-ONCOLOGY



TIRELL JOHNSON, MD
HEAD & NECK



ANDREW KUYKENDALL, MD
MPN



UMAIR MAJEED, MBBS, MD
LIVER



CLAUDIA PABA PRADA, MD
MYELOMA



GUILHERME RABINOWITS, MD
THROAT



GURU SONPAVDE, MD
BLADDER



JONATHAN TRENT, MD
GIST



CHRISTIANA SHAW, MD, MS, FACS
SKIN



GEORGE SIMON, MD, FACP, FCCP
LUNG



VICTORIA RIZK, MD
BREAST



LEONARDO BORREGALES, MD
KIDNEY



JUSTIN WATTS, MD
AML



AHMED ZAKARI, MD
PANCREATIC



SARBAJIT MUKHERJEE, MD, MS
STOMACH

Thank
You!

COMMITTEES, CONSORTIUMS, & WORKING GROUP HIGHLIGHTS

FLASCO's impact is powered by the **collective expertise and passion of our committees**. These diverse groups serve as the engine of our society, transforming our mission of Advocacy, Education, and Communication into tangible action.

MEMBERSHIP COMMITTEE

PROGRAM CHAIR: CHAKRA CHAULAGAIN, MD
CLEVELAND CLINIC FLORIDA



In 2025, FLASCO continued to strengthen its statewide, multidisciplinary community, reaching major membership milestones and expanding engagement across clinicians, trainees, and allied professionals. Growth was especially strong among affiliate, student, and early-career members, reinforcing FLASCO's role as a long-term professional home for oncology teams across Florida.

- Total membership growth exceeded 20% year over year
- Continued expansion across disciplines and practice settings

PROGRAM COMMITTEE

PROGRAM CHAIR: FAITHLORE GARDNER, MD
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE



The Program Committee oversaw one of FLASCO's most comprehensive education years to date, delivering high impact programming across disease states, disciplines, and career stages. From major congresses to focused Clinical Oncology Series and certification prep courses, programming emphasized real-world relevance, multidisciplinary learning, and statewide reach.

- Spring & Fall Congresses, Clinical Oncology Series, OCN Prep Courses, and specialty summits
- Broad clinician and industry engagement across Florida

CLINICAL PRACTICE COMMITTEE

PROGRAM CHAIR: MIKE CUSNIR, MD
MOUNT SINAI MEDICAL CENTER MIAMI BEACH



The Clinical Practice Committee elevated real-world challenges facing oncology practices, including payer denials, drug shortages, and variability in access to new therapies. Discussions throughout the year reinforced the importance of timely, practical education that reflects how care is delivered in everyday practice.

- Focus on frontline implementation challenges
- Identification of opportunities to better support members navigating rapid change

FELLOWS, RESIDENTS & EARLY CAREER INITIATIVES

RICK MCDONOUGH, MD
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE



FLASCO expanded its commitment to developing the next generation of oncology professionals through travel awards, research opportunities, and growing participation across multiple FLASCO educational events. Engagement emphasized mentorship, professional development, and connection to Florida's oncology community.

- Trainee participation across Congresses and poster sessions
- Invested in the professional growth of trainees through exclusive Travel Award Grants designed to expand knowledge and build lasting networks.

RN CONSORTIUM

PROGRAM CHAIRS: MARY MACKRELL, RN, MSN, MED, OCN, BMTCN, & JOY ORONOS, RN, OCN, MSN-NE, MEMORIAL HEALTHCARE



The RN Consortium focused on supporting oncology nurses through targeted education, certification preparation, and community building. Programming reflected direct member input and the evolving needs of Florida oncology nurses.

- OCN Prep Courses delivered
- Expanded education and engagement planned

LEGISLATIVE COMMITTEE

PROGRAM CHAIRS: PARESH PATEL, MD & MICHAEL DIAZ, MD
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE



FLASCO's advocacy efforts in 2025 focused on protecting patient access and supporting oncology practices amid increasing payer and policy complexity. The committee closely monitored legislation impacting cancer care and worked with state and national partners to elevate oncology priorities in Florida.

- Monitoring legislation related to CAR-T coverage, PBM reform, copay accumulators, and biomarker testing
- Joint letters, advocacy roundtables, and ongoing policymaker engagement

BYLAWS COMMITTEE

PROGRAM CHAIR: THOMAS GEORGE, MD, FACP
UF CANCER INSTITUTE



In 2025, the Bylaws Committee led a review and update of FLASCO's governing documents to ensure the organization's structure continues to support growth, transparency, and effective leadership. Updates approved at the FLASCO Spring Congress Board Meeting modernized governance processes and clarified leadership roles.

- Approved updates to FLASCO bylaws
- Strengthened officer election processes and leadership continuity

ETHICS COMMITTEE

ASHWIN MEHTA, MD
MEMORIAL HEALTHCARE SYSTEM



FLASCO formalized its commitment to ethical leadership in 2025 through the implementation of a new Ethics Policy and Code of Business Conduct. The policy establishes clear expectations for professional conduct, transparency, and conflict-of-interest management across all FLASCO activities.

- New Ethics Policy and Code of Business Conduct adopted
- Standardized ethics and COI disclosures across leadership and committees

CORPORATE PARTNER COLLABORATIONS

ADVANCING PRACTICE THROUGH SHARED PURPOSE



FLASCO's corporate partnerships are grounded in more than sponsorship. They are built on shared goals, mutual trust, and a commitment to advancing oncology care across Florida. By aligning clinical insight with industry expertise, FLASCO and its corporate partners collaborate to identify real-world gaps in care and develop initiatives that are relevant, timely, and practice-changing.

In 2025, FLASCO collaborated with industry partners to drive initiatives that went beyond traditional educational support. These projects directly addressed gaps in care, from genomic and biomarker testing to health equity, access, and care coordination. Each collaboration was intentionally designed to generate insight, foster multidisciplinary dialogue, and translate frontline experience into meaningful impact across our organizations and for the patients we collectively serve.

FLASCO MEMBER LEADERSHIP AND PARTICIPATION

The success of these initiatives is driven by FLASCO's members. FLASCO extends its sincere gratitude to the physicians, advanced practice providers, pharmacists, and oncology professionals who participated in surveys, shared their real-world experience and clinical expertise, and contributed as faculty, moderators, and speakers through podcasts, roundtables, and recorded programs. Their leadership, engagement, and willingness to openly examine challenges ensure that FLASCO's work remains clinician-led, evidence-informed, and grounded in the realities of oncology practice. Through their contributions, these members helped transform collaborative ideas into impactful initiatives that benefit FLASCO, its corporate partners, and patients across Florida.



ALEXION

FLASCO Member Leadership: Michael Jaglal, MD; Moazzam Shahzad, MD; Kathy Fu, MD

PERSPECTIVES ON MALIGNANCY AND DRUG-INDUCED AHUS

ADVANCING RECOGNITION AND MANAGEMENT OF AHUS IN ONCOLOGY

In 2025, FLASCO partnered with Alexion, a FLASCO Elite Partner, to better understand how atypical hemolytic uremic syndrome (aHUS), particularly when triggered by malignancy or cancer therapies, is recognized and managed across oncology practices in Florida. Although aHUS is rare, it carries significant morbidity, and delayed diagnosis or uncertainty in management can result in serious clinical consequences. Through a statewide survey of oncology clinicians across practice settings, FLASCO gathered real-world insights into diagnostic patterns, suspected triggers, treatment decision-making, and care coordination challenges associated with malignancy- and drug-induced aHUS.

Analysis of the 2025 survey data revealed meaningful variability in recognition, diagnostic workup, and management approaches, reinforcing the complexity of this condition and the need for concise, practice-relevant guidance. These findings are informing the development of future FLASCO educational resources, including a faculty-led micro-learning program planned for release in 2026. This work reflects FLASCO's commitment to addressing rare but high-impact clinical scenarios by translating member-driven insights into practical education that supports earlier recognition, informed decision-making, and multidisciplinary care.



AMGEN

FLASCO Member Leadership: Jose Sandoval-Sus, MD; Dina Dumercy McHenry, PharmD; Matthew Chui, MD; Jose Alemar, MD; Brooke Adams, PharmD

BRIDGING THE EMERGENCY RESPONSE GAP

ED TEAMS ON BISPECIFIC-ASSOCIATED CRS AND ICAN

In 2025, FLASCO partnered with Amgen, to address a growing patient safety challenge as the use of bispecific antibodies expands across oncology practice in Florida. While oncology teams are trained to recognize and manage immune-mediated toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), patients often present to emergency departments or urgent care settings where familiarity with these syndromes is limited. To better understand real-world gaps, FLASCO convened multidisciplinary roundtable discussions bringing together oncologists, pharmacists, and emergency medicine providers to share experiences, identify barriers to timely recognition, and discuss opportunities to improve care coordination.

Insights from these 2025 roundtables reinforced the need for practical, easily accessible guidance for non-oncology clinicians who may encounter patients receiving bispecific therapies. The discussions highlighted variability in recognition, uncertainty around escalation pathways, and challenges in communication between oncology and emergency teams. These findings are informing the next phase of this collaboration, which will focus on translating frontline insights into a simple educational resource designed to support earlier recognition and appropriate management of CRS and ICANS in emergency settings. This project reflects FLASCO's commitment to strengthening continuity of care across disciplines and ensuring that advances in cancer therapy are matched by readiness throughout the broader healthcare system in Florida.



BRISTOL MYERS SQUIBB
 FLASCO Member Leadership: Ahmed Zakari, MD; Chinmay Jani, MD

POWER UNDER THE SKIN

EXPLORING SUBQ IMMUNOTHERAPY IN PRACTICE

As subcutaneous immunotherapy options continue to expand, oncology practices across Florida are evaluating how these therapies may influence workflow, capacity, and patient experience. Through this project, FLASCO partnered with BMS, a FLASCO Presidential Partner, to capture real-world perspectives on the adoption and use of subcutaneous immunotherapy across diverse practice settings. A statewide survey engaged physicians, advanced practice providers, pharmacists, and nurses from community practices, hospital-based programs, and academic centers throughout Florida.

Survey findings highlighted both opportunity and complexity. Respondents identified potential benefits related to reduced treatment administration time, infusion chair utilization, and patient convenience, alongside challenges such as reimbursement considerations, payer coverage, training needs, and operational readiness. The variability in responses reflected differences in infrastructure and resources across practice environments. By elevating frontline clinician insights, this project reinforces FLASCO's role in informing future education and dialogue around emerging care delivery models and supporting oncology practices as they adapt to evolving therapeutic options across Florida.



GENENTECH
 FLASCO Member Leadership: Estelamari Rodriguez, MD; Heather Augustniak, DNP; Edgardo Santos, MD

GENENTECH

ADVANCING WOMEN-CENTRIC CANCER CARE IN FLORIDA

Women-centric cancer care emerged as a key focus area for FLASCO in 2025 through a strategic collaboration with Genentech, a FLASCO Elite Partner. Building on shared priorities around equity, access, and patient-centered care, FLASCO convened multi-stakeholder roundtables in Orlando, Doral, and Miami, as well as a dedicated discussion during the FLASCO Fall Session. These conversations brought together oncology clinicians, administrators, professional associations, health plans, employers, advocacy organizations, and elected officials to align on the most pressing challenges impacting women's health across Florida's cancer care landscape.

Through this work, FLASCO and Genentech identified clear focus areas, including provider and policy education, normalizing patient-provider dialogue, reducing access barriers such as wait times and prior authorizations, and improving patient resources and benefit awareness. A multi-stakeholder working group was established to advance this work collaboratively, recognizing that meaningful progress requires engagement across the healthcare ecosystem. Together, these efforts elevated women's health within the oncology community and laid the groundwork for prioritized solutions to be advanced in 2026, reinforcing FLASCO's commitment to improving outcomes for women and, in turn, the health of families and communities across Florida.



Oncology

GILEAD

FLASCO Member Leadership: Maen Hussein, MD

THE ART OF TREATING **METASTATIC TRIPLE NEGATIVE BREAST CANCER** EVOLVING OPTIONS, EMERGING INSIGHTS

SURVEY IN COLLABORATION WITH GILEAD SCIENCES

To better understand real-world treatment decision-making in metastatic triple-negative breast cancer (mTNBC), FLASCO initiated a new collaboration with Gilead Sciences in 2025 focused on evaluating how evolving therapeutic options are being applied in routine oncology practice across Florida. Central to this effort is a statewide survey designed to explore clinician familiarity with, and use of, antibody-drug conjugates (ADCs), as well as the clinical, operational, and access-related factors that influence treatment selection across lines of therapy.

The survey is actively being distributed to oncology clinicians across diverse practice settings and regions of Florida, with data collection continuing into 2026 to strengthen the depth and representativeness of insights. Responses will help identify practice patterns, barriers to guideline-concordant care, and opportunities to better support oncology teams managing mTNBC. Findings from this work are intended to inform future FLASCO education and resources focused on closing gaps between emerging evidence and real-world practice, with the goal of improving patient experience and access to recommended therapies statewide.



JAZZ PHARMACEUTICALS

FLASCO Member Leadership: Paresh Patel, MD; Noman Ashraf, MD; Umair Majeed, MD

ADVANCING CARE IN GI AND BILIARY TRACT CANCERS

In collaboration with Jazz Pharmaceuticals, FLASCO launched a four-part podcast series focused on advancing care in gastrointestinal and biliary tract cancers. Designed to support real-world oncology practice, the series addresses biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA), with emphasis on disease state education, multidisciplinary team coordination, HER2 testing, and the evolving role of targeted therapies. Two episodes were published in 2025, featuring expert faculty discussions on BTC disease presentation, diagnostic workup, first-line management, and the importance of multidisciplinary collaboration, as well as practical guidance on HER2 testing in BTC and GEA.

The remaining two episodes, scheduled for release in 2026, will build on this foundation by exploring HER2-directed therapies across gastrointestinal malignancies, including differences in mechanisms of action, safety considerations, and patient selection, followed by a focused discussion on GEA disease management and emerging treatment strategies. Moderated by a clinical expert to ensure continuity and practical relevance, the series reflects FLASCO's commitment to delivering accessible, high-value education through innovative formats.



Johnson & Johnson

JOHNSON & JOHNSON
FLASCO Member Leadership: Ariel Grajales, MD; Sikander Ailawadhi, MD; Paba Prada, MD; Ivan Borello, MD

IMPROVING COMMUNITY ACCESS TO CAR-T AND BISPECIFIC THERAPIES IN MYELOMA

FLASCO launched a statewide initiative in collaboration with Johnson & Johnson to address barriers limiting patient access to CAR-T and bispecific therapies for multiple myeloma in Florida. While these therapies are increasingly incorporated into treatment guidelines, their initiation and management remain largely centralized within academic centers, creating variability in access for patients treated in community oncology settings. To better understand these gaps, FLASCO convened a series of multidisciplinary roundtables bringing together academic experts and community oncology teams to discuss real-world experiences, challenges, and opportunities related to referral pathways, step-up dosing, maintenance therapy, and post-CAR-T supportive care.

Roundtables were held in Aventura, Jacksonville, and Orlando, with a final session scheduled for January 15 in Tampa. Discussions focused on clinical readiness, staffing and infrastructure needs, financial and operational considerations, and differences in protocols across practice settings. Insights gathered through this initiative will be synthesized into a white paper summarizing key findings and practical considerations for expanding safe, effective community participation in CAR-T and bispecific care. This work reflects FLASCO's commitment to creating better access to life-changing therapies for patients and supporting more consistent, high-quality myeloma care across Florida.



PFIZER

FLASCO Member Leadership: Guru Sonpavde, MD; Winston Tan, MD; Mike Cusnir, MD; Maen Hussein, MD; Chinmay Jani, MD; Ali Al-Sbihi, MD; Nayef Abdel-Razeq, MD

ADDRESSING BARRIERS TO GUIDELINE-CONCORDANT CARE IN ADVANCED BLADDER CANCER

FLASCO partnered with Pfizer to examine real-world treatment patterns and barriers to guideline-concordant care in first-line advanced bladder cancer across Florida. Building on emerging claims data showing underutilization of preferred regimens, FLASCO conducted a statewide provider survey to better understand clinical decision-making, confidence in managing adverse events, institutional barriers, and resource needs related to the use of antibody-drug conjugate and immune checkpoint inhibitor combinations. Findings from this work were developed into a scientific abstract highlighting treatment patterns and barriers within Florida and submitted for national dissemination.

To further contextualize these findings and promote multidisciplinary dialogue, FLASCO convened regional roundtable discussions with oncology providers in Jacksonville, Tampa, Orlando, and South Florida. These conversations explored variation in practice patterns, challenges related to patient comorbidities, insurance approval delays, financial toxicity, and coordination of care. In addition to informing near-term education efforts, this initiative established a foundation for FLASCO to continue advancing real-world data efforts in advanced bladder cancer by bringing together key stakeholders committed to improving guideline adoption and patient access to optimal therapy across Florida.



STEMLINE THERAPEUTICS
FLASCO Member Leadership:
Wassim McHayleh, MD

INSIDE ESRI **HOW MUTATION TESTING SHAPES BREAST CANCER CARE**

FLASCO partnered with Stemline Therapeutics, a Menarini company and FLASCO Elite Corporate Partner, to better understand real-world practices related to ESRI mutation testing in estrogen receptor-positive, HER2-negative metastatic breast cancer. As new therapies emerge and the clinical relevance of ESRI mutations continues to evolve, FLASCO launched a statewide survey to assess when and how ESRI testing is ordered, how results influence treatment decisions, and what barriers exist in accessing or interpreting testing across oncology practices in Florida.

Insights from the survey informed the development of a FLASCO-led podcast episode titled Inside ESRI: How Mutation Testing Shapes Breast Cancer Care. This episode explored the clinical implications of both acquired and intrinsic ESRI mutations, drawing on real-world survey findings to highlight current testing practices, challenges, and opportunities for more personalized care. This content was developed independently by FLASCO and reflects the organization's commitment to translating member-driven insights into practical education that supports informed decision-making and improved care for patients with hormone receptor-positive breast cancer across Florida.



TAKEDA ONCOLOGY
FLASCO Member Leadership: Tiago
Biachi, MD; Raji Shameem, MD

VOICES IN COLORECTAL CANCER **CONVERSATIONS THAT ADVANCE MCRC CARE**

FLASCO partnered with Takeda Oncology to elevate discussion around the evolving management of metastatic colorectal cancer (mCRC) through a dedicated podcast series, Voices in Colorectal Cancer: Conversations that Advance mCRC Care. Designed to address persistent education gaps, particularly in community oncology settings, the series focused on disease state trends, application of NCCN guidelines, treatment sequencing, and the changing demographics of mCRC, including the rise of early-onset disease. Episodes were informed by FLASCO member insights and structured to reflect real-world challenges faced by oncology teams across Florida.

Through expert-led conversations, the series examined critical issues such as late-stage presentation, barriers to timely screening, variability in molecular profiling and treatment decisions, and the role of the multidisciplinary care team in addressing social determinants of health, survivorship, and patient quality of life. By centering practical experiences and emerging evidence, this collaboration contributed to greater awareness of gaps in care delivery and reinforced the importance of coordinated, patient-centered approaches to improving outcomes for individuals living with mCRC across Florida.

2025 FLASCO CORPORATE PARTNERS



ALEXION
ASTRAZENECA
BEONE MEDICINES
BOEHRINGER INGELHEIM
DAIICHI SANKYO, INC.
GENENTECH
GILEAD
GSK
INCYTE
JAZZ PHARMACEUTICALS
JOHNSON & JOHNSON
REGENERON
SANOFI
STEMLINE THERAPEUTICS,
A MENARINI COMPANY
TAKEDA ONCOLOGY

ASTELLAS PHARMA
BLUEPRINT MEDICINES
GENMAB
GERON
IPSEN BIOPHARMACEUTICALS
PHARMAESSENTIA

ADC THERAPEUTICS
DECIPHERA PHARMACEUTICALS
EISAI
EMD SERONO
FOUNDATION MEDICINE
GRAIL
GUARDANT HEALTH
KARYOPHARM THERAPEUTICS
KITE PHARMA
KURA ONCOLOGY
LILLY ONCOLOGY
NOVARTIS
SOBI, INC.
SUMITOMO PHARMA
TAIHO ONCOLOGY



ACROTECH BIOPHARMA
ADAPTIVE BIOTECHNOLOGIES
AGIOS PHARMACEUTICALS
APELLIS PHARMACEUTICALS
AVEO ONCOLOGY (AN LG CHEM
COMPANY)
BAYER
BIOTHERANOSTICS (A HOLOGIC
COMPANY)
BLUE EARTH DIAGNOSTICS, INC.
CARIS LIFE SCIENCES
CASTLE BIOSCIENCES
CELLTRION
CENCORA
COHERUS

DENDREON
EAGLE PHARMACEUTICALS
EXELIXIS
IMMUNOCORE, LLC
IOVANCE BIOTHERAPEUTICS
NATERA
NORTHSTAR (BY BILLIONTOONE)
NOVOCURE
PRECISEDx
RIGEL PHARMACEUTICALS
SPRINGWORKS THERAPEUTICS
SYNDAX PHARMACEUTICALS
TEMPUS AI



IN LOVING MEMORY OF DOROTHY GREEN PHILLIPS FORMER EXECUTIVE DIRECTOR, FLASCO



It is with profound gratitude for her life and legacy that the Florida Society of Clinical Oncology remembers Dorothy Green Phillips, a visionary leader who guided our organization with passion, grace, and unwavering dedication for nearly two decades.

Dorothy's remarkable career in cancer advocacy spanned more than fifty years, including three decades of service with the American Cancer Society. In the early 2000s, she took the helm as FLASCO's Executive Director, transforming the society into the vibrant, impactful organization it is today. Under her stewardship, FLASCO became more than a professional network; it became a collaborative community uniting physicians, patients, and partners in a shared mission to advance cancer care.

Her influence extended far beyond Florida. As a national voice on the ASCO State Affiliate Committee, Dorothy championed the vital role of state societies across the country. Even after her retirement in 2020, she remained a tireless advocate, working to strengthen partnerships across the oncology landscape.

To those who knew her, Dorothy was a force of nature—warm, thoughtful, and fiercely committed to the people she served. She was not only a leader but a mentor and friend to countless oncology professionals.

Dorothy leaves behind a loving family, including three children, five grandchildren, and thirteen great-grandchildren. She will be laid to rest with her beloved dachshund, Synamin. While she is no longer with us, her spirit remains woven into the fabric of this society. We are a stronger, more connected community because of her.